“A first-of-its-kind vaccine for acute myeloid leukemia, a deadly blood cancer, succeeded in a Phase 3 clinical trial, drugmaker Sellas Life Sciences and Memorial Sloan Kettering Cancer Center announced Tuesday, marking another positive result in a breakthrough year for cancer vaccines.
Patients given the vaccine, galinpepimut-S (GPS), had a 41 percent reduction in risk of death compared with those given other treatments for leukemia, according to Sellas, which presented initial data from a trial of 126 patients.
GPS was tested on patients who achieved a second or later complete remission for leukemia, meaning patients who were successfully treated for the disease at least twice. Acute myeloid leukemia, which affects around 20,000 people a year in the United States, is usually treated with chemotherapy, but remnants of the cancer often remain, and recurrence is common.
The results come after another cancer vaccine, intismeran, succeeded in a Phase 3 trial for treating melanoma earlier this year. GPS differs from it in a key way: While intismeran is a personalized mRNA vaccine that requires a sample from a patient’s tumor to produce on a case-by-case basis, GPS is designed to treat all patients with the same drug.”
From Washington Post.